Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Merck Is Shopping for Smarts In Hep C

The pharma giant says it's determined to be the leader in treatments for the disease -- a market that is expected to hit $20 billion by 2020.

Idenix and Achillion Jump on Takeover Talk

Their hepatitis C drugs could be lures for Big Pharma after a rival gets a juicy offer from Bristol-Myers Squibb.

Why Disposing of Stericycle Shares May Be Right Move

Despite dropping by more than 10% since October, Stericycle shares still have more room below it. But the company does have a few options to reassure investors.

Dendreon Jumps 40% on Provenge Sales

Dendreon saw its stock jump Thursday as sales of its cancer drug beat the expectations of both analysts and the company itself.

Teva’s New CEO Is Battle-Tested. Good Thing

Drug industry vet Jeremy Levin earned his stripes making deals for Bristol-Myers Squibb, but he'll face tough going at the generic-drug maker.

Mead Johnson Bounce Followed J&J Script

Mead Johnson's recent Enfamil scare sent many investors packing -- but those who stuck with the stock could soon be rewarded.

FDA, Insurers Demand Tests for New Drugs

Pressure on pharmaceutical companies for evidence that their drugs work is fueling a surge in the global market for "companion diagnostics."

2011’s Best and Worst Picks From InvestorPlace’s Barry Cohen

Barry Cohen discusses some of his picks from 2011 -- and how that will affect his take on companies moving forward.

Walgreen Not Sweating Loss of Express Scripts Customers to CVS — Should It Be?

CVS says it could gobble up to 23M prescriptions that Walgreens has sold through Express Scripts if a deal isn't announced. So far, WAG is sticking to its guns.

Ariad Pharmaceuticals Still Might Have Upside

Ariad Pharmaceuticals is up 120% in the past 12 months, mostly fueled on optimism over its trial leukemia treatment. But some analysts think the ceiling is higher.